All patients 
                     adolescents (typically 12-15 years of age)  adults (typically between 18 and 65yr)  age >= 55 yr  age >= 60 yr  age >= 65 yr  age >= 75 yr  alpha variant (B.1.1.7, UK)  any cancer  autoimmune disease  beta variant (B.1.351 / 501Y.V2, South Africa)  children  corticosteroids: no  corticosteroids: yes  critical disease  delta variant (B.1.617.2, Indian)  dialysis patients  elderly (typically over 65yr)  fully vaccinated  gamma variant (P.1, Brazil)  haematological cancers   healthcare workers  immunodepression  invasive ventilation  kidney transplant recipients  no oxygen needed  non invasive oxygen  obese  omicron variant BA.1 (B.1.1.529)  omicron variant BA.2 VOC  original (Wuhan) strain  positive for SARS-Cov-2 at baseline  severe disease  solid cancer  solid organ transplant recipients  subjects at risk  
                  
            
            
         
        
        
        
        
        
        
            potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results  VERU-111, 2022 0.30 [0.14; 0.64]
 0.30 [0.14 ; 0.64 ] VERU-111, 2022 1 0% 150 NA not evaluable death D28detailed results  CAN-COVID, 2020 0.67 [0.30; 1.50]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
FACCT Trial, 2021 0.69 [0.28; 1.68]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Pandit, 2021 0.95 [0.02; 50.33]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
 0.60 [0.45 ; 0.79 ] CAN-COVID, 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Krolewiecki, 2020, Pandit, 2021, RAPID (Sholzberg), 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 12 0% 4,186 moderate low death or transfer to ICUdetailed results  RAPID (Sholzberg), 2021 0.70 [0.44; 1.12]
 0.70 [0.44 ; 1.12 ] RAPID (Sholzberg), 2021 1 0% 465 NA not evaluable deathsdetailed results  ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.64 [0.18; 2.24]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.09 [0.31; 3.84]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
Dabbous HM, 2020 0.51 [0.02; 15.41]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Fu, 2020 1.00 [0.02; 51.66]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Khamis, 2020 0.83 [0.23; 2.96]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Libster, 2020 0.50 [0.09; 2.71]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
NCT04542694, 2020 1.00 [0.02; 50.90]
Pandit, 2021 0.95 [0.02; 50.33]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
Udwadia, 2020 0.50 [0.02; 15.03]
 0.70 [0.59 ; 0.83 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, CAN-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, Dabbous HM, 2020, FACCT Trial, 2021, Fu, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Krolewiecki, 2020, Libster, 2020, LIVE-AIR (Temesgen), 2021, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, RAPID (Sholzberg), 2021, SAVE-MORE, 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Udwadia, 2020 26 0% 9,758 moderate critical deaths (time to event analysis only)detailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.64 [0.18; 2.24]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
 0.68 [0.43 ; 1.08 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, LIVE-AIR (Temesgen), 2021 4 0% 1,620 moderate not evaluable clinical deteriorationdetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.99 [0.57; 1.72]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
I-TECH (Lim), 2022 1.25 [0.87; 1.80]
Li T, 2020 0.48 [0.01; 27.44]
Libster, 2020 0.52 [0.29; 0.94]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
RAPID (Sholzberg), 2021 0.69 [0.43; 1.10]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
 0.73 [0.51 ; 1.04 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, I-TECH (Lim), 2022, Li T, 2020, Libster, 2020, NCT04523831 (Mahmud), 2020, RAPID (Sholzberg), 2021, SAVE-MORE, 2021 12 70% 2,540 moderate low clinical improvementdetailed results  AVIFAVIR, 2020 0.53 [0.13; 2.19]
CAN-COVID, 2020 1.39 [0.76; 2.54]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.81 [0.54; 1.22]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
Ghandehari, 2020 1.31 [1.00; 1.71]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Udwadia, 2020 1.75 [1.10; 2.79]
 1.31 [1.09 ; 1.58 ] AVIFAVIR, 2020, CAN-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, Ghandehari, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Udwadia, 2020 12 41% 3,279 moderate low clinical improvement (14-day)detailed results  AVIFAVIR, 2020 0.53 [0.13; 2.19]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1.01 [0.58; 1.76]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
Pandit, 2021 8.77 [0.94; 81.67]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
 1.17 [0.93 ; 1.47 ] AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 9 35% 2,516 moderate not evaluable clinical improvement (21-day)detailed results  Li T, 2020 2.09 [0.04; 119.96]
 2.09 [0.04 ; 119.96 ] Li T, 2020 1 0% 18 NA not evaluable clinical improvement (28-day)detailed results  ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57]
GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Udwadia, 2020 1.75 [1.10; 2.79]
 1.34 [1.10 ; 1.62 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020, Udwadia, 2020 5 46% 3,321 moderate serious clinical improvement (7-day)detailed results  COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
Kirti, 2021 0.90 [0.77; 1.06]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
 1.31 [1.01 ; 1.69 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kirti, 2021, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021 8 71% 2,180 moderate serious clinical improvement (time to event analysis only)detailed results  FACCT Trial, 2021 0.85 [0.62; 1.16]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Shinkai, 2021 1.40 [0.91; 2.15]
Udwadia, 2020 1.75 [1.10; 2.79]
 1.28 [1.06 ; 1.54 ] FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 7 54% 1,924 moderate not evaluable death or ventilationdetailed results  ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07]
CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
RAPID (Sholzberg), 2021 0.59 [0.34; 1.02]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
 0.75 [0.63 ; 0.88 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, CORIMUNO-ANA-1, 2021, LIVE-AIR (Temesgen), 2021, RAPID (Sholzberg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 5 0% 4,009 moderate not evaluable hospital dischargedetailed results  FACCT Trial, 2021 0.88 [0.64; 1.21]
Kirti, 2021 1.20 [0.73; 1.98]
Li T, 2020 10.00 [1.03; 97.50]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
Udwadia, 2020 1.41 [0.97; 2.03]
 1.25 [0.92 ; 1.70 ] FACCT Trial, 2021, Kirti, 2021, Li T, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Udwadia, 2020 5 56% 1,731 moderate not evaluable hospitalizationdetailed results  Jagannathan, 2020 1.00 [0.14; 7.34]
 1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1.77 [0.81; 3.87]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Kirti, 2021 0.20 [0.00; 8.69]
Li T, 2020 0.40 [0.04; 3.90]
RAPID (Sholzberg), 2021 0.70 [0.32; 1.54]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Udwadia, 2020 0.06 [0.01; 0.83]
 0.66 [0.37 ; 1.17 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Kirti, 2021, Li T, 2020, RAPID (Sholzberg), 2021, SAVE-MORE, 2021, Udwadia, 2020 11 37% 3,256 moderate critical mechanical ventilation (time to event analysis only)detailed results  Udwadia, 2020 0.06 [0.01; 0.83]
 0.06 [0.01 ; 0.83 ] Udwadia, 2020 1 0% 14 NA not evaluable radiologic improvement (14-day)detailed results  ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
 1.82 [0.95 ; 3.51 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021 4 39% 450 moderate not evaluable radiologic improvement (7-day)detailed results  ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
 0.09 [0.01 ; 0.78 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020 2 0% 46 moderate not evaluable viral clearance detailed results  AVIFAVIR, 2020 3.89 [1.23; 12.29]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Jagannathan, 2020 0.81 [0.56; 1.18]
NCT04542694, 2020 13.03 [2.96; 57.24]
Pandit, 2021 2.33 [0.55; 9.83]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Udwadia, 2020 1.37 [0.94; 1.98]
 1.50 [1.08 ; 2.07 ] AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Jagannathan, 2020, NCT04542694, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Udwadia, 2020 11 70% 1,153 moderate critical viral clearance (time to event analysis only)detailed results  Jagannathan, 2020 0.81 [0.56; 1.18]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Udwadia, 2020 1.37 [0.94; 1.98]
 1.13 [0.83 ; 1.55 ] Jagannathan, 2020, Ruzhentsova T, 2020, Udwadia, 2020 3 56% 438 moderate not evaluable viral clearance by day 14detailed results  AVIFAVIR, 2020 3.08 [0.62; 15.39]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Li T, 2020 1.00 [0.03; 34.67]
Pandit, 2021 10.23 [1.12; 93.35]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
 0.81 [0.10 ; 6.83 ] AVIFAVIR, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Li T, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 7 95% 1,656 moderate not evaluable viral clearance by day 7detailed results  AVIFAVIR, 2020 3.89 [1.23; 12.29]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
Kirti, 2021 0.80 [0.43; 1.50]
Pandit, 2021 2.33 [0.55; 9.83]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
 1.17 [0.90 ; 1.53 ] AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirti, 2021, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 9 60% 795 moderate not evaluable ICU admissiondetailed results  COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
FACCT Trial, 2021 1.42 [0.79; 2.55]
I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Khamis, 2020 1.03 [0.35; 3.03]
Kirti, 2021 0.90 [0.30; 2.70]
Libster, 2020 0.33 [0.07; 1.58]
RAPID (Sholzberg), 2021 0.79 [0.48; 1.30]
 0.91 [0.67 ; 1.25 ] COL-COVID (Pascual-Figal), 2021, FACCT Trial, 2021, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Libster, 2020, RAPID (Sholzberg), 2021 7 0% 1,673 moderate not evaluable recoverydetailed results  Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
 1.13 [0.98 ; 1.31 ] Crippa (CANDIDATE), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 887 moderate not evaluable serious adverse eventsdetailed results  CAN-COVID, 2020 0.73 [0.45; 1.19]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1.87 [0.36; 9.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
Jagannathan, 2020 1.00 [0.14; 7.34]
Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
NCT04542694, 2020 6.15 [0.30; 124.49]
Pandit, 2021 0.95 [0.02; 50.33]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Shinkai, 2021 2.80 [0.14; 56.95]
Udwadia, 2020 1.03 [0.02; 52.48]
 0.75 [0.54 ; 1.04 ] CAN-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Jagannathan, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 14 0% 3,423 moderate critical acute kidney injury detailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1.18 [0.44; 3.18]
 1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results  Chaccour, 2020 1.00 [0.20; 5.07]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 2.22 [1.43; 3.44]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
Jagannathan, 2020 1.33 [0.63; 2.78]
Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
NCT04542694, 2020 1.00 [0.54; 1.85]
Pandit, 2021 1.68 [0.47; 5.97]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Shinkai, 2021 19.54 [7.77; 49.11]
Udwadia, 2020 6.36 [2.43; 16.65]
 1.89 [1.34 ; 2.68 ] Chaccour, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Jagannathan, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 15 72% 3,331 moderate low arrhythmiadetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 2.24 [0.23; 21.69]
 2.24 [0.23 ; 21.69 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1 0% 416 NA not evaluable elevated liver enzymesdetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 3.48 [1.40; 8.64]
 3.48 [1.40 ; 8.64 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1 0% 416 NA not evaluable long QTdetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 9.79 [1.27; 75.50]
 9.79 [1.27 ; 75.50 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1 0% 174 NA not evaluable Major bleedingdetailed results  ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67]
 1.80 [0.88 ; 3.67 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1 0% 2,227 NA not evaluable renal impairmentdetailed results  COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
 1.35 [0.47 ; 3.86 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1 0% 331 NA not evaluable Thromboembolic  eventsdetailed results  Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 0.89 [0.31; 2.55]
 0.89 [0.31 ; 2.55 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ  AZI, 2020 1 0% 345 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2025-10-31 06:53 +01:00 
                TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); 
                k: number of studies; n: total number of patients;
                ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
                
         
        
        
        
            pathologies: 90
    - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
    - roots T: 290